Benzene Ring Nonionically Bonded Patents (Class 514/567)
  • Patent number: 11110073
    Abstract: The present invention relates to a stable, aqueous, injectable solution comprising diclofenac and polyvinylpyrrolidone. The present invention also relates to processes for preparing the injectable solution.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: September 7, 2021
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Sushilkumar Dhanaji Patil, Nirav Ishwarlal Khatri, Alex Kochukunju George, Sushrut Krishnaji Kulkarni
  • Patent number: 11096915
    Abstract: Described is a method for the preparation of an oral levothyroxine composition, comprising the steps of combining levothyroxine or a salt thereof, a water-miscible organic solvent or a sugar alcohol and water, adjusting the pH to at least 8 providing a basic aqueous medium, dissolving the levothyroxine in the basic aqueous medium to yield a levothyroxine solution, and lowering the pH of the levothyroxine solution to between 3.5-4.9. also described is an oral levothyroxine composition obtainable by the said method and its use as a medicament.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: August 24, 2021
    Assignee: EMP Levo US B.V.
    Inventors: Yannis Psarrakis, Konstantinos Lioumis
  • Patent number: 11096913
    Abstract: The invention relates to highly stable alcohol-free, water-glycerol solutions of T4 thyroid hormone, with a reduced amount of T3 impurity, packaged via specific container arrangements. The containers are multi-barrier ones, in which a number of layers of specific materials separate the solution from contact with the external environment.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: August 24, 2021
    Assignee: ALTERGON SA
    Inventors: Tiziano Fossati, Lorenzo Bellorini, Marco Pizzutti
  • Patent number: 11033513
    Abstract: A method for treatment of irritation or damage to conical or conjunctival epithelial cells, particularly for irritation or damage to corneal or conjunctival epithelial cells due to severe Sjögren's syndrome, by applying topically to an affected eye an aqueous solution of glycerol characterized by a glycerol concentration of >1% (w/v), most preferably 2.5% (w/v). The method is effective even in the case of very low tear formation, and its effectiveness cannot be explained by the known humectant effect of glycerol.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: June 15, 2021
    Assignee: Resdevco Research and Development Co. Ltd.
    Inventor: Shabtay Dikstein
  • Patent number: 11000523
    Abstract: The present disclosure relates to a new pharmaceutical composition comprising Ceritinib. Particularly it is directed to the tablet that is prepared by wet granulation, wherein povidone is used as a binder. Further feature of the composition is that the drug and the binder form the inner phase, whereas all other excipients are added in a powder form as an outer phase. This way, the sticking of the composition is prevented and sufficient tablet hardness can be reached.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: May 11, 2021
    Inventors: Sebastien Breulles, Simon Ensslin
  • Patent number: 11000495
    Abstract: The invention relates to beneficial topical pharmaceutical compositions comprising diclofenac sodium in high amounts, and methods for their use. Said compositions represent emulsion-gels as well as gels with unique properties such as high skin penetration, no irritation, high stability, complete dissolution of the active and effective pain relief. The invention also provides methods for treating pain or inflammation in a mammalian subject in need thereof, including acute and chronic pain or inflammation; and kits therefor.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: May 11, 2021
    Assignee: GSK Consumer Healthcare S.A.
    Inventors: Gregory Johnson, Eric Woodward
  • Patent number: 10980757
    Abstract: Ready-to-use, stable aqueous intravenous tranexamic acid compositions are provided.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: April 20, 2021
    Assignee: RTU Pharma SA
    Inventors: Thomas Jacobsen, Eric Dubois
  • Patent number: 10933042
    Abstract: An intravenous baclofen solution is disclosed, along with methods of dosing and treatment therewith.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: March 2, 2021
    Assignees: Allaysis, LLC, Regents of the University of Minnesota
    Inventors: James C. Cloyd, Adolfo L. Gomez, Linda Krach, Robert L. Kriel, John Schrogie, Stephen John Tucker, Rob Tuohy
  • Patent number: 10836708
    Abstract: Provided herein are processes, compounds and compositions for making (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid. Also provided herein a pharmaceutical compositions containing (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: November 17, 2020
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Richard B. Silverman, Matthew Moschitto
  • Patent number: 10751303
    Abstract: Methods of shortening the duration of anti-infective therapy and increasing the effectiveness of anti-infective drugs in subjects with infection are present. The methods are based on altering the replication rate of a pathogen, which makes the pathogen more susceptible to the actions of the anti-infective drug.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: August 25, 2020
    Assignee: INSTITUTE FOR CLINICAL PHARMACODYNAMICS, INC.
    Inventor: Paul G. Ambrose
  • Patent number: 10729716
    Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: August 4, 2020
    Assignee: CXL OPHTHALMICS, LLC
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Patent number: 10624839
    Abstract: Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: April 21, 2020
    Assignee: NeuroDerm, Ltd.
    Inventor: Oron Yacoby-Zeevi
  • Patent number: 10537538
    Abstract: The invention relates to highly stable alcohol-free, water-glycerol solutions of T4 thyroid hormone, with a reduced amount of T3 impurity, packaged via specific container arrangements. The containers are multi-barrier ones, in which a number of layers of specific materials separate the solution from contact with the external environment.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: January 21, 2020
    Assignee: Altergon SA
    Inventors: Tiziano Fossati, Lorenzo Bellorini, Marco Pizzutti
  • Patent number: 10441573
    Abstract: The present invention relates to the use of DBH inhibitors (e.g., disulfiram and Nepicastat), and pharmaceutical compositions thereof, for treating subjects with certain types of memory loss, for instance memory loss associated with a neurodegenerative disease, disorder, or condition, such as Alzheimer's Disease.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: October 15, 2019
    Assignee: Brandeis University
    Inventor: John Lisman
  • Patent number: 10426836
    Abstract: The present inventions relate generally to compositions, kits, and methods for the treatment of stress-related disorders, including but not limited to post-traumatic stress disorder.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: October 1, 2019
    Assignee: Hoffman Technologies, Inc.
    Inventor: Steven Hoffman
  • Patent number: 10377698
    Abstract: Diphenethylamine derivatives for use as highly active analgesics, diuretics, anxiolytics, for the treatment of neurodegenerative, psychiatric and neuropsychiatric disorders, and also as anti-itch, anti-addiction, anti-inflammatory, anti-obesity, anti-epileptic, anti-convulsant, anti-seizure, anti-stress, anti-psychotic and anti-depressant medications and their pharmaceutically acceptable salts and easily accessible derivatives thereof (e.g. esters, ethers, amides), processes for their preparation and their application in the manufacture of pharmaceutical products.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: August 13, 2019
    Assignee: University of Innsbruck
    Inventors: Helmut Schmidhammer, Mariana Spetea, Elena Guerrieri
  • Patent number: 10307404
    Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: June 4, 2019
    Assignee: PanOptica, Inc.
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • Patent number: 10258585
    Abstract: Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: April 16, 2019
    Assignee: NeuroDerm, Ltd.
    Inventor: Oron Yacoby-Zeevi
  • Patent number: 10092549
    Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 9, 2018
    Assignee: PanOptica, Inc.
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • Patent number: 10028927
    Abstract: Herein described is a topical composition for application of an NSAID, the composition comprising a solution or suspension of the NSAID as active ingredient in a residual carrier system comprising a polyhydric alcohol, a glycol ether, an ester of a higher fatty acid and water, and the ingredients of the residual carrier system have the following concentrations in percentages by weight::polyhydric alcohol 50-90%; glycol ether 7.5-40%; ester 0.5-5%; and water up to 10%. Either the composition or the residual carrier system is a single phase at ambient conditions. The composition may also comprise a volatile solvent such as ethanol or isopropyl alcohol.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: July 24, 2018
    Assignee: FUTURA MEDICAL DEVELOPMENTS LIMITED
    Inventor: Adrian Davis
  • Patent number: 9782376
    Abstract: The present invention is directed to a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes tromethamine, sodium iodide, and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: October 10, 2017
    Assignee: Fresenius Kabi USA LLC
    Inventors: Arunya Usayapant, Basma M. Ibrahim
  • Patent number: 9707197
    Abstract: The composition comprises 0.5% to 10% by weight of a neuropathic analgesic; 0.5% to 10% by weight of a muscle relaxant; 0.5% to 20% by weight of an anti-inflammatory analgesic; and 0.5% to 10% by weight of an anesthetic.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: July 18, 2017
    Assignee: Multimode Medical Inc.
    Inventor: Patrick Musitano
  • Patent number: 9682923
    Abstract: The present disclosure is directed in part to methods of treating fibrosis, e.g., hepatic fibrosis and/or intestinal fibrosis, comprising administering to a patient in need thereof an effective amount of a disclosed compound.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: June 20, 2017
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Patent number: 9636316
    Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid ? toxicity. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on baclofen and acamprosate combination.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: May 2, 2017
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Emmanuel Vial, Mickael Guedj
  • Patent number: 9622996
    Abstract: A method for treating an cancer disease is disclosed comprising administering to a subject a pharmaceutical composition comprising an adrenergic beta-3-receptor blocker.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: April 18, 2017
    Inventors: Shuguang Lin, Meng Zheng
  • Patent number: 9610269
    Abstract: The present invention discloses a method of treating a disease condition susceptible to baclofen therapy, said method comprising orally administering once-a-day in the evening a controlled release drug delivery system comprising baclofen or its pharmaceutically acceptable salt or its derivatives and pharmaceutically acceptable excipients.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: April 4, 2017
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Nitin Bhalachandra Dharmadhikari, Yashoraj Rupsinh Zala
  • Patent number: 9579385
    Abstract: Compositions and methods related to ophthalmic use of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: February 28, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Anuradha V. Gore, Chetan P. Pujara, Richard S. Graham, Melissa Gulmezian, Kristin Prinn, Ramakrishnan Srikumar
  • Patent number: 9561277
    Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: February 7, 2017
    Assignee: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Shirou Sawa, Shuhei Fujita
  • Patent number: 9555025
    Abstract: Provided is an ointment which has excellent drug stability and excellent drug uniformity. The ointment, which comprises 1 to 5% by weight of 1-[2-[(4S)-4-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(hydroxymethyl)-6,7-dimethoxynaphthalene·3/2 hydrate, 3 to 7% by weight of a separation inhibitor, 15 to 50% by weight of a hydrocarbon gel, a pH controller and 0.05 to 0.4% by weight of an antioxidant, has excellent drug stability and excellent drug dispersibility. In the present ointment, polyoxyethylene (196) polyoxypropylene (67) glycol is preferred as the separation inhibitor, diisopropanolamine is preferred as the pH controller, and dibutylhydroxytoluene is preferred as the antioxidant.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: January 31, 2017
    Assignees: Maruho Co., Ltd., Mitsubishi Tanabe Pharma Corporation
    Inventors: Tomoki Sakaguchi, Hidetoshi Emi
  • Patent number: 9504650
    Abstract: A pharmaceutical composition for intranasal administration for human subjects includes vitamin B12 and a pharmaceutically acceptable carrier. The vitamin B12 particles are dispersed in a hydrophobic continuous phase as the pharmaceutically acceptable carrier. The dispersion of solid vitamin B12 particles (crystals or amorphic) in a hydrophobic continuous phase displays very satisfactory bioavailability. Also, the intense red color is reduced significantly, making the pharmaceutical composition acceptable for intranasal use.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: November 29, 2016
    Inventor: Klaas Alouis Riepma
  • Patent number: 9427446
    Abstract: The invention relates to a stable injectable aqueous solution containing diclofenac and thiocolchicoside, or pharmaceutically acceptable salts thereof, and the use thereof in the treatment of painful and inflammatory rheumatic or traumatic conditions of the joints, muscles, tendons and ligaments.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: August 30, 2016
    Assignee: EPIFARMA S.R.L.
    Inventors: Giuseppe Irianni, Cristina Macelloni, Luca Teseschi
  • Patent number: 9381255
    Abstract: Nanoparticles comprising T3 and their use in treating, e.g., cardiac conditions, for example cardiac arrest, are provided. Such nanoparticles provide improved delivery of T3 and allow for acute treatment and optionally for sustained release of T3 in a patient.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: July 5, 2016
    Assignee: AVANT GARDE THERAPEUTICS AND TECHNOLOGIES LLC
    Inventors: Leo Rubin, Shaker Mousa
  • Patent number: 9371297
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: June 21, 2016
    Assignee: Ocera Therapeutics, Inc.
    Inventors: Hamid Hoveyda, Graeme L. Fraser, Kamel Benakli, Sophie Beauchemin, Martin Brassard, Eric Marsault, Luc Oullet, Mark L. Peterson, Zhigang Wang
  • Patent number: 9364453
    Abstract: The present disclosure relates to a more effective therapeutic agent capable of improving and treating the axial symptoms (particularly freezing of gait symptom) of patients with Parkinson's disease. Such symptoms in patients with Parkinson's disease can be improved and treated by using L-threo-3,4-dihydroxy-phenylserine (DOPS) and a COMT inhibitor in combination together, optionally with an L-DOPA preparation as well. As a result, the axial symptoms difficult to improve with conventional L-DOPA preparations can be treated, and a therapeutic agent and a treatment method are provided for the axial symptoms of patients with Parkinson's disease, particularly those suffering from the disease at a moderate level or higher.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: June 14, 2016
    Assignee: Lundbeck NA Ltd.
    Inventors: Saburo Sakoda, Kei Fukada
  • Patent number: 9271961
    Abstract: The invention includes compositions comprising selective AKR1C3 inhibitors. The invention also includes compositions comprising bifunctional AKR1C3 inhibitors and selective androgen receptor modulators. The invention further includes methods of treatment using the compositions of the invention.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: March 1, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Trevor M. Penning, Adegoke O. Adeniji, Michael C. Burns, Jeffrey Winkler, Barry Twenter
  • Patent number: 9238016
    Abstract: The present invention relates to a novel antibiotic, and more specifically relates to an antibiotic composition comprising flufenamic acid as an active ingredient, which can reduce drug toxicity and side effects and the problem of antibiotic resistance caused by excessive use of antibiotics since the composition exhibits a good therapeutic effect, even in a small dose, when it is administered either alone or together with another antibiotic of the prior art.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: January 19, 2016
    Assignee: SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION
    Inventors: Kyeong Kyu Kim, Sung Wook Kang
  • Patent number: 9180108
    Abstract: Methods for preparing sterilized baclofen solutions include adjusting the pH to below a desired pH, and steam sterilizing the solution with adjusted pH, which results in the solution having the desired pH. Such solutions may also have low concentrations of 4-CPP. Injectable baclofen solutions having greater than 2 mg/mL baclofen include between 5 mM and 25 mM of a phosphate or sulfate species. The solution has an ionic strength equivalent of about 1.5 M NaCl. The present application also provides baclofen formulations for use in treating spasticity, brain injury, cerebral palsy, spinal cord injury, cervical injury, multiple sclerosis, thoracic injury, or withdrawal symptoms.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: November 10, 2015
    Assignee: Medtronic, Inc.
    Inventors: Michael C. Schmitz, Corinne Dominguez, Thomas E. Keene, Deanna S. Lane, Lanchi T. Le, Jianwei Li, Ngoc T. Lu, Carmen E. Snaza
  • Patent number: 9168238
    Abstract: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a lyophilized solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 2 to 4 milligrams mannitol.
    Type: Grant
    Filed: March 8, 2015
    Date of Patent: October 27, 2015
    Assignee: Fresenius Kabi USA, LLC
    Inventors: John Zhiqiang Jiang, Arunya Usayapant, George Monen
  • Patent number: 9168239
    Abstract: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a lyophilized solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 2 to 4 milligrams mannitol.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: October 27, 2015
    Assignee: Fresenius Kabi USA, LLC
    Inventors: John Zhiqiang Jiang, Arunya Usayapant, George Monen
  • Patent number: 9101645
    Abstract: The invention relates generally to treatment of neurological disorders and nervous system injuries. The invention specifically provides methods of using modulators of particular target proteins to modulate degeneration of neurons or portions thereof, such as axons.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: August 11, 2015
    Assignee: Genentech, Inc.
    Inventors: Ryan Watts, Mark Chen, Joseph Wesley Lewcock, Christine Pozniak, Arundhati Sengupta-Ghosh
  • Patent number: 9061968
    Abstract: Different polymorphs of bromfenac sodium may be prepared and interconverted using crystallization/recrystallization, drying and/or hydration techniques.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: June 23, 2015
    Assignee: Johnson Matthey Public Limited Company
    Inventors: Saroop Singh Matharu, Gurijala Venu Reddy, James J. Mencel, Xiaoyong Sun
  • Patent number: 9056814
    Abstract: The present invention relates to the crystalline, polymorphic Form C of the calcimimetic compound {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, to methods of preparation thereof, to methods of characterization thereof by single crystal X-Ray crystallography (XRC), X-Ray Powder diffractometry, attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, Solid State NMR spectroscopy and Differential Scanning Calorimetry (DSC), and to its use.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: June 16, 2015
    Assignee: LEO PHARMA A/S
    Inventors: Soren Ebdrup, Kim Troensegaard Nielsen, Tanja Maria Greve
  • Patent number: 9050307
    Abstract: Levothyroxine, also known as L-thyroxine, synthetic T4, or 3,5,3?,5?-tetraiodo-L-thyronine, CAS number 51-48-9, is a synthetic form of thyroxine, used as a hormone substitute for patients with thyroid conditions. The invention relates to a method for the preparation of an oral levothyroxine composition. The method according to the invention results in liquid levothyroxine formulations that have improved storage stability compared to known liquid levothyroxine formulations.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: June 9, 2015
    Assignee: EMP Pharma GmbH
    Inventors: Yannis Psarrakis, Konstantinos I. Lioumis
  • Publication number: 20150148355
    Abstract: A silicone gel (“silogel”) composition used to deliver pharmaceutical products transdermally as well as a method for producing the silogel composition, which may contain up to 80% additive ingredients. Preferred embodiments of the invention may include silogel compositions which provide high viscosity/no separation due to API. They are not temperature-sensitive, have no shear stress from the ointment mill/EMP, have no gumming up/stickiness, and no hardening.
    Type: Application
    Filed: November 24, 2014
    Publication date: May 28, 2015
    Inventor: John Olin Trimble
  • Publication number: 20150147282
    Abstract: The present invention relates to topical bioadhesive formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.
    Type: Application
    Filed: November 24, 2014
    Publication date: May 28, 2015
    Inventors: Fredrik JOABSSON, Margareta LINDEN, Krister THURESSON, Fredrik TIBERG
  • Publication number: 20150147385
    Abstract: Compositions and methods for the treatment of proliferative disorders including proliferative such as breast, uterine cervical, ophthalmic, and pancreatic cancer by the administration of intravenous synthetic curcumin (S-curcumin) are disclosed herein.
    Type: Application
    Filed: November 21, 2014
    Publication date: May 28, 2015
    Inventor: Lawrence Helson
  • Publication number: 20150147320
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Application
    Filed: December 16, 2014
    Publication date: May 28, 2015
    Inventors: SHEUE-FANG SHIH, PO-CHUN CHANG, YUN-LONG TSENG, LUKE S.S. GUO, KEELUNG HONG
  • Publication number: 20150148325
    Abstract: The invention provides extended release pro-liposomal, non-aqueous, pharmaceutical formulations of a hydrophobic active pharmaceutical ingredient (API) of low water solubility but readily dissolved in alcohols and methods for making same. The formulations can be administered by infiltration into an incision, or by injection.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 28, 2015
    Inventors: Shimon Amselem, Michael Naveh
  • Publication number: 20150147281
    Abstract: Provided are methods, test devices, and diagnostic kits for predicting, assessing, and diagnosing the risk of a disease using salivary analysis. The methods comprise providing a whole (unfractionated) saliva sample from a subject; contacting an aliquot of the saliva with two or more lectins under conditions that allow the two or more lectins to bind to a lectin-binding component of the saliva; detecting the amount of bound lectin; and comparing the amount of bound lectin to the amount known to bind a saliva sample from a control patient, to predict the risk of a disease in the subject. Also provided are methods for reducing the risk of a disease and a method for assessing the risk of the disease at a defined level.
    Type: Application
    Filed: November 17, 2014
    Publication date: May 28, 2015
    Inventors: Patricia A. Denny, Paul C. Denny, Mahvash Navazesh
  • Publication number: 20150148420
    Abstract: Methods for treating insomnia are disclosed. The methods are directed to administering a pharmaceutically effective amount of baclofen to an individual suffering from insomnia. In addition, due to baclofen's positive effects on reducing nighttime reflux events, the present methods are directed to treating insomnia in patients that also suffer from nighttime reflux or gastroesophageal reflux disease (GERD) by administering a pharmaceutically effective amount of baclofen.
    Type: Application
    Filed: March 13, 2013
    Publication date: May 28, 2015
    Inventor: William C. Orr